TNG260 is a Small-Molecule CoREST Inhibitor that Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy

By afschroeder • August 30, 2025

Ahronian LG, Sahu S, Zhang M, Patel AS, Geng K, Bhattacharya R, Falchook GS, Goldman JW, Spira AI, Punekar SR, Spigel DR, Wang JS, Skoulidis F, Stephens J, Meynardie M, Powell JM, Lopez A, Ranieri M, Ploszaj MA, Tan YJ, Lee YT, Yu Y, Deng J, Chen T, McCarren P, Tsai A, Hussain SS, Doyon B, Amemiya K, Ermolieff J, Shahagadkar P, Das NM, Flynn LR, Shields JA, Danielczyk L, McMillan BJ, Mignault A, Meier SR, Wu HJ, Guerin DJ, Whittington DA, Min C, Sienczylo I, Maxwell JP, DiBenedetto HJ, Watanabe H, Haines BB, Huang A, Crystal A, Andersen JN, Wu X, Wong KK. TNG260 is a Small-Molecule CoREST Inhibitor that Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy. Cancer Res. 2025 Aug 29. doi: 10.1158/0008-5472.CAN-25-0998. Epub ahead of print. PMID: 40882030.

Tags: Hematology/Oncology, Publications

Chemotherapy-Induced Biological Age Acceleration and Lifetime Outcomes in Breast Cancer Survivors

Sarkar S, Sedrak MS, Carroll JE, Schechter C, Muss HB, Mandelblatt JS. Chemotherapy-Induced Biological Age Acceleration and Lifetime Outcomes in Breast Cancer Survivors. JAMA Netw[...]

Engineered stem cell-derived CD16-enhanced universal NKT cells improve monoclonal antibody-based cancer immunotherapy

Li YR, Zhu Y, Yu Y, Kramer A, Shao Z, Chen Y, Shen X, Zhang C, Ma N, Zhao A, Ochoa CJ, DiBernardo GA, Yuen[...]

daNIS-2: a phase III, randomized, double-blind study of the anti-TGF-β monoclonal antibody NIS793 or placebo in combination with nab-paclitaxel/gemcitabine as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma

Paulson S, Ikeda M, Shen L, Stein A, Macarulla T, Milella M, Golan T, Wainberg Z, Taieb J, Wang L, Polydoros F, Abecunas C, López[...]